How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
A novel study reveals that targeting a single protein’s aggregation can dramatically reduce brain injury after stroke, potentially transforming how acute ischemic strokes are treated. Study: ...
This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results